These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35794607)

  • 41. Using Time Trade-Off Values to Estimate EQ-5D-Y Value Sets: An Exploratory Study.
    Yang Z; Jiang J; Wang P; Wu J; Fang Y; Feng D; Xi X; Luo N
    Value Health; 2023 Jul; 26(7):968-973. PubMed ID: 36921897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age dependency of EQ-5D-Youth health states valuations on a visual analogue scale.
    Retra JGA; Essers BAB; Joore MA; Evers SMAA; Dirksen CD
    Health Qual Life Outcomes; 2020 Dec; 18(1):386. PubMed ID: 33308228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
    Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
    Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Development of the German version of EQ-5D-Y-5L to measure health-related quality of life in children and adolescents: Identification of response labels and pilot testing].
    Kreimeier S; Greiner W
    Z Evid Fortbild Qual Gesundhwes; 2019 Aug; 144-145():24-34. PubMed ID: 31378708
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
    Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
    Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead'.
    Sullivan T; Hansen P; Ombler F; Derrett S; Devlin N
    Soc Sci Med; 2020 Feb; 246():112707. PubMed ID: 31945596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
    Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
    Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time and lexicographic preferences in the valuation of EQ-5D-Y with time trade-off methodology.
    Lipman SA; Zhang L; Shah KK; Attema AE
    Eur J Health Econ; 2023 Mar; 24(2):293-305. PubMed ID: 35596831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Why Do Adults Value EQ-5D-Y-3L Health States Differently for Themselves Than for Children and Adolescents: A Think-Aloud Study.
    Reckers-Droog V; Karimi M; Lipman S; Verstraete J
    Value Health; 2022 Jul; 25(7):1174-1184. PubMed ID: 35168891
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
    Karim S; Craig BM; Groothuis-Oudshoorn CGM
    Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of online and face-to-face valuation of the EQ-5D-5L using composite time trade-off.
    Jiang R; Shaw J; Mühlbacher A; Lee TA; Walton S; Kohlmann T; Norman R; Pickard AS
    Qual Life Res; 2021 May; 30(5):1433-1444. PubMed ID: 33247810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valuing health-related quality of life: An EQ-5D-5L value set for England.
    Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
    Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utilities of the EQ-5D: transferable or not?
    Knies S; Evers SM; Candel MJ; Severens JL; Ament AJ
    Pharmacoeconomics; 2009; 27(9):767-79. PubMed ID: 19757870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
    Gandhi M; Rand K; Luo N
    Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?
    Devlin NJ; Pan T; Sculpher M; Jit M; Stolk E; Rowen D; van Hout B; Norman R
    Pharmacoeconomics; 2023 Oct; 41(10):1165-1174. PubMed ID: 37439998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In search of a 'pan-European value set'; application for EQ-5D-3L.
    Sajjad A; Versteegh MM; Santi I; Busschbach J; Simon J; Roijen LH
    BMC Med Res Methodol; 2023 Jan; 23(1):13. PubMed ID: 36635625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states.
    Schneider PP; van Hout B; Heisen M; Brazier J; Devlin N
    Wellcome Open Res; 2022; 7():14. PubMed ID: 36060298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study.
    Ryan JM; McKay E; Anokye N; Noorkoiv M; Theis N; Lavelle G
    BMJ Open; 2020 Sep; 10(9):e037089. PubMed ID: 32912983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.